Status:
UNKNOWN
Study of Drug Therapy for Pediatric Heart Failure
Lead Sponsor:
China National Center for Cardiovascular Diseases
Collaborating Sponsors:
Peking University First Hospital
Beijing Children's Hospital
Conditions:
Heart Failure Congenital
Eligibility:
All Genders
Up to 14 years
Brief Summary
The goal of this observational study is to compare the safety and effectiveness of a modified drug therapy with traditional drug therapy in pediatric heart failure patients. The main questions it aim...
Eligibility Criteria
Inclusion
- Patients younger than 14 years of age
- heart failure after congenital heart surgery
- Ross \> 2 or NYHA \> 2
- LVEF\<55%, or LVFS\<25%
Exclusion
- single ventricle
- congenital heart disease without anatomical correction
- Patients with heart failure requiring ventricular assist or cardiac synchronization therapy
- Patients with severe pulmonary hypertension (pulmonary arterial pressure \>6 Wood·U)
- Patients with severe liver and kidney failure
- Patients who are allergic to related medications
- Patients with symptomatic hypotension who cannot tolerate related drugs
- Refuse to sign the informed consent or refuse to participate in this experiment
Key Trial Info
Start Date :
January 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06039540
Start Date
January 1 2022
End Date
December 31 2024
Last Update
September 15 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fuwai hospital
Beijing, Beijing Municipality, China, 100037